Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

April 29th 2020

Neeraj Agarwal, MD, discusses the tolerability of apalutamide in metastatic castration-sensitive prostate cancer.

Dr. Shinohara on Radiation Therapy Considerations in Prostate Cancer

April 28th 2020

Eric Shinohara, MD, MSCI, discusses radiation therapy considerations for patients with prostate cancer.

Dr. Parker on the Optimal Timing of Salvage Therapy in Prostate Cancer

April 27th 2020

Chris Parker, MD, discusses the optimal timing of salvage radiotherapy for men with prostate cancer.

Dr. Concepcion on Current Testing Patterns in Urology Practices

April 25th 2020

Raoul S. Concepcion, MD, FACS, director, Comprehensive Prostate Center, discusses current testing patterns in urology practices.

Dr. Mohler on Recommendations for Genetic Testing in Prostate Cancer

April 25th 2020

James L. Mohler, MD, professor of oncology, associate director, and senior vice president of Translational Research, chief of Inter-Institutional Academics at Roswell Park Comprehensive Cancer Center, discusses recommendations for performing genetic testing in prostate cancer.

Dr. McKay on Evaluating Radium-223 in HRD-Mutant mCRPC

April 25th 2020

Rana R. McKay, MD, assistant professor of medicine and medical oncologist at the University of California, San Diego, discusses planned research in which investigators will evaluate the use of radium-223 dichloride (Xofigo) in patients with homologous recombination deficiency (HRD)-mutant metastatic castration-resistant prostate cancer (mCRPC).

Dr. Beltran on Using cfDNA to Detect Castration-Resistant Neuroendocrine Prostate Cancer

April 25th 2020

Himisha Beltran, MD, discusses profiling of circulating tumor DNA to detect castration-resistant neuroendocrine prostate cancer.

Sipuleucel-T Plus Radium-223 Improves Clinical Outcomes in Bone-Metastatic CRPC

April 24th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the efficacy of radium-223 plus sipuleucel-T in patients with bone-metastatic castration-resistant prostate cancer and the next steps for research for this combination.

Olaparib Improves Survival in HRR-Mutant mCRPC

April 24th 2020

Olaparib improved overall survival in previously treated patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene mutations.

Dr. Hamid on Next Steps for Precision Medicine in mHSPC

April 24th 2020

Anis Hamid, MBBS, discusses next steps for precision medicine in metastatic hormone sensitive prostate cancer.

Dr. Hwang on the Utility of Docetaxel in mCSPC

April 24th 2020

Clara Hwang, MD, discusses the utility of docetaxel and abiraterone acetate in metastatic castration-sensitive prostate cancer.

Dr. Chang on Questions Regarding Molecular Testing in Prostate Cancer

April 23rd 2020

Sam S. Chang, MD, MBA, discusses remaining questions regarding molecular testing in prostate cancer.

Dr. Oh on the Importance of Identifying DNA Damage Repair Mutations in Prostate Cancer

April 23rd 2020

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Real-World Analysis Supports Upfront Use of Radium-223 in mCRPC

April 22nd 2020

Rana R. McKay, MD, discusses the results of the real-world analysis with radium-223 and other exciting research in the mCRPC field.

Dr. Pettaway on the Prevalence of Germline Mutations in Diverse Populations With Prostate Cancer

April 22nd 2020

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate Cancer

April 22nd 2020

Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.

FDA Approval Sought for Relugolix in Prostate Cancer

April 21st 2020

A New Drug Application has been submitted to the FDA for single-agent relugolix for use as a treatment for men with advanced prostate cancer.

Dr. Parker on the Rationale for the RADICALS-RT Trial in Prostate Cancer

April 20th 2020

Chris Parker, MD, discusses the rationale for the phase III RADICALS-RT trial in prostate cancer.

Dr. Tagawa on Ongoing Research With 225Ac-J591 in mCRPC

April 17th 2020

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Morris on OS Data With Apalutamide in Prostate Cancer

April 15th 2020

David Morris, MD, FACS, discusses overall survival data with apalutamide in prostate cancer.